Search research articles
Contact Us
Filters
Showing results (131-140 of 250) with videos related to
Page
of 25
Sort By:
Arthritis and Rheumatism
|
October 2, 2007
Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach
Didier Lefranc, David Launay, Sylvain Dubucquoi, et al.
Neurology
|
May 22, 2020
Asymptomatic optic nerve lesions: An underestimated cause of silent retinal atrophy in MS
Jean-Baptiste Davion, Renaud Lopes, Élodie Drumez, et al.
Plos One
|
July 2, 2015
An Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies
Virginie Dutoit-Lefèvre, Sylvain Dubucquoi, David Launay, et al.
The New England Journal of Medicine
|
January 22, 2010
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
Gavin Giovannoni, Giancarlo Comi, Stuart Cook, et al.
Ophthalmology
|
November 2, 2010
Kjellin syndrome: long-term neuro-ophthalmologic follow-up and novel mutations in the SPG11 gene
Bernard Puech, Arnaud Lacour, Giovanni Stevanin, et al.
Journal of Neurology
|
December 25, 2012
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
Giancarlo Comi, Stuart D Cook, Gavin Giovannoni, et al.
Frontiers in Immunology
|
June 29, 2026
Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis
Celia Oreja-Guevara, Sven G Meuth, Nikos Grigoriadis, et al.
Therapeutic Advances in Neurological Disorders
|
December 13, 2021
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
Peter Rieckmann, Diego Centonze, Gavin Giovannoni, et al.
Muscle & Nerve
|
November 19, 2016
Bent spine syndrome as the initial symptom of late-onset Pompe disease
Nicolas Taisne, Claude Desnuelle, Raul Juntas Morales, et al.
Annals of Neurology
|
August 30, 2018
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
Jerry S Wolinsky, Xavier Montalban, Stephen L Hauser, et al.
Page
of 25
Search research articles
Search
Showing results (131-140 of 250) with videos related to
Sort By:
Page
of 25
Arthritis and Rheumatism
|
October 2, 2007
Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach
Didier Lefranc, David Launay, Sylvain Dubucquoi, et al.
Neurology
|
May 22, 2020
Asymptomatic optic nerve lesions: An underestimated cause of silent retinal atrophy in MS
Jean-Baptiste Davion, Renaud Lopes, Élodie Drumez, et al.
Plos One
|
July 2, 2015
An Optimized Fluorescence-Based Bidimensional Immunoproteomic Approach for Accurate Screening of Autoantibodies
Virginie Dutoit-Lefèvre, Sylvain Dubucquoi, David Launay, et al.
The New England Journal of Medicine
|
January 22, 2010
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
Gavin Giovannoni, Giancarlo Comi, Stuart Cook, et al.
Ophthalmology
|
November 2, 2010
Kjellin syndrome: long-term neuro-ophthalmologic follow-up and novel mutations in the SPG11 gene
Bernard Puech, Arnaud Lacour, Giovanni Stevanin, et al.
Journal of Neurology
|
December 25, 2012
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study
Giancarlo Comi, Stuart D Cook, Gavin Giovannoni, et al.
Frontiers in Immunology
|
June 29, 2026
Modulation of the immunological and neuroinflammatory microenvironment in older people with multiple sclerosis
Celia Oreja-Guevara, Sven G Meuth, Nikos Grigoriadis, et al.
Therapeutic Advances in Neurological Disorders
|
December 13, 2021
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
Peter Rieckmann, Diego Centonze, Gavin Giovannoni, et al.
Muscle & Nerve
|
November 19, 2016
Bent spine syndrome as the initial symptom of late-onset Pompe disease
Nicolas Taisne, Claude Desnuelle, Raul Juntas Morales, et al.
Annals of Neurology
|
August 30, 2018
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
Jerry S Wolinsky, Xavier Montalban, Stephen L Hauser, et al.
Page
of 25